SCHEMBL4188090

SCHEMBL4188090

CCOC(C)Oc1ccccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
L3MBTL1 Q9Y468 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HTR2C P28335 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23906795 0.86 LMNA (0.48) ADRA2AADRA2BADRA2CL3MBTL1ALDH1A1
SCHEMBL10709666 0.84 ADRA2A (0.49) ADRA2AADRA2BADRA2CL3MBTL1ALDH1A1
SCHEMBL27701197 0.79 CA1 (0.50) ADRA2AADRA2BADRA2CL3MBTL1ALDH1A1
SCHEMBL13086759 0.79 CYP1A2 (0.41) ADRA2BL3MBTL1ALDH1A1HPGDMEN1
SCHEMBL8218163 0.79 ADRA2A (0.48) ADRA2AADRA2BADRA2CL3MBTL1ALDH1A1
SCHEMBL11454473 0.79 SMN1; SMN2 (0.52) L3MBTL1ALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL4201350 0.78 LMNA (0.39) ADRA2AADRA2BADRA2CL3MBTL1ALDH1A1
SCHEMBL20314717 0.78 NISCH (0.42) ADRA2AADRA2BADRA2CL3MBTL1ALDH1A1
SCHEMBL11554545 0.78 TSHR (0.45) ALDH1A1HPGDMAPTLMNA
SCHEMBL20637343 0.78 LMNA (0.39) ADRA2AADRA2BADRA2CL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521581-B2 Catalyst composition and process for producing cross-coupled compound using same TOSOH CORPORATION (JP) 2009-04-21 US disclosed
EP-1707263-B1 Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same TOSOH CORP (JP) 2009-02-25 EP disclosed
US-20060224011-A1 Catalyst composition and process for producing cross-coupled compound using same TOSOH CORPORATION 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060224011-A1 Catalyst composition and process for producing cross-coupled compound using same C5, TST, PYM1 ADRA2A 2385/4885ADRA2B 2016/4885ADRA2C 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.